Saturday 17 October 2026 Export BDX’s income statement to Excel — free account

Becton, Dickinson and Company

BDX Healthcare Medical Instruments & Supplies

In the quarter to June 2026, revenue grew 5.44%, EPS fell 31.5%, free cash flow fell 31.6% and total debt fell 22.9%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for three.

191.75 2.01 −1.04%

Follow BDX

Alert me

Market cap: $52.8B
P/E: 57.8×
Fwd P/E: 37.7×
Dividend yield: 2.07%
F-score: 7/9
Altman Z: 1.84
Beneish M: −2.64
Dividend safety: 67/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 2.77

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	3	2	2	1	1	1	4	1	3	1	—

Insider Ownership 1.08%

Capital & Financial Ratios $m

Market Cap 52,780.00

Revenue 22,415.00

Net Income 942.00

Free Cash Flow 3,203.00

Net Debt 12,647.00

Current Ratio 0.87

Debt/Equity 0.55

P/E ratio 57.76

Fwd P/E 37.70

P/S ratio 2.35

P/B ratio 2.16

Past 5Y EPS Growth 16.52%

This Y EPS Growth 11.98%

Next Y EPS Growth 4.50%

Next Y revenue growth (11.74%)

Next 5Y EPS Growth 7.75%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 82.33%

10-year low 10-year high

P/S against its own 10 years 23.70%

10-year low 10-year high

P/B against its own 10 years 35.46%

10-year low 10-year high

EV/Sales against its own 10 years 15.04%

10-year low 10-year high

EV/FCF against its own 10 years 14.74%

10-year low 10-year high

Dividends

Payout Ratio 1.20

Annual Dividend Rate 3.98

Annual Dividend Yield 2.07%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	3.92	1.05 1.05 1.05
2025	3.28	0.82 0.82 0.82 0.83
2024	3.06	0.75 0.75 0.75 0.82
2023	2.89	0.72 0.72 0.72 0.75
2022	2.75	0.67 0.68 0.68 0.72
2021	2.58	0.64 0.64 0.64 0.67
2020	2.45	0.61 0.61 0.61 0.64
2019	2.38	0.59 0.59 0.59 0.61
2018	2.32	0.58 0.58 0.58 0.59
2017	2.25	0.56 0.56 0.56 0.58
2016	2.08	0.51 0.51 0.51 0.56

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,489	2,301	859	864
Receivables	2,534	3,033	2,994	2,364
Inventory	3,273	3,843	3,894	3,316
Other	—	—	—	—
	8,676	10,468	9,255	8,139

	2023	2024	2025	Q'26
Payables	1,641	1,896	1,974	6,107
ST’ Debt	—	—	—	—
Other	—	6,777	6,753	6,107
	6,641	8,956	8,313	9,404

Compound Annual Growth %

	10y	5y	3y
Sales	7.82%	6.32%	4.99%
Cash Flow	7.08%	3.15%	11.55%
Earnings	9.21%	16.95%	(0.22%)
Book Value	13.49%	1.33%	0.14%

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	5,252	4,714	4,983	—	—
’25	5,168	4,480	4,726	7,466	21,840
’24	4,706	5,045	4,990	5,437	20,178
’23	4,586	4,821	4,878	5,087	19,372
’22	4,718	4,750	4,641	4,761	18,870
’21	5,315	4,907	4,607	4,302	19,131
’20	4,225	4,253	3,855	3,741	16,074

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	657	671	776	—	—
’25	693	(204)	1,089	1,852	3,430
’24	855	514	1,297	1,178	3,844
’23	399	185	1,081	1,325	2,990
’22	530	290	678	973	2,471
’21	1,533	1,188	564	841	4,126
’20	713	483	862	879	2,937

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	549	546	633	—	—
’25	588	(318)	925	1,475	2,670
’24	739	380	1,118	882	3,119
’23	191	4	890	1,031	2,116
’22	347	68	425	658	1,498
’21	1,287	935	321	389	2,932
’20	540	261	660	707	2,168

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	1.34	(1.11)	1.37	—	—
’25	1.04	1.07	2.00	1.72	5.82
’24	0.96	1.85	1.68	1.45	5.93
’23	1.70	1.53	1.36	0.37	4.94
’22	2.28	1.50	1.18	0.92	5.88
’21	3.35	0.94	1.72	0.84	6.85
’20	0.87	0.53	0.97	0.36	2.71

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	99.33	123.87	160.01	161.62	151.67	180.34	169.73	179.73	171.97	127.59	Analyst estimates 2026–2028 Powerpack
	High	139.41	176.17	203.92	211.29	219.91	205.07	218.00	225.88	196.45	198.11
People
People	Employees	50,928	41,933	76,032	70,093	65,000	70,000	77,000	73,000	74,000	72,000
	Revenue/emp, $m	0.25	0.29	0.21	0.25	0.25	0.27	0.25	0.27	0.27	0.30
Income, $m
Income, $m	Revenue	12,483	12,093	15,983	17,290	16,074	19,131	18,870	19,372	20,178	21,840
	Gross margin, %	47.99	49.33	45.48	47.94	42.29	45.12	44.92	42.17	45.22	45.44
	EBT	1,074	976	1,173	1,176	414	1,692	1,783	1,662	2,005	1,881
	EBT margin, %	8.60	8.07	7.34	6.80	2.58	8.84	9.45	8.58	9.94	8.61
	Net income	976	1,100	311	1,233	874	2,092	1,779	1,484	1,705	1,678
	Depreciation	1,114	1,088	1,978	2,253	2,115	2,230	2,229	2,288	2,286	2,462
Per share, $
Per share, $	Revenue	58.69	55.23	61.86	64.05	57.62	66.13	66.21	67.67	69.64	75.93
	Earnings	4.59	4.70	0.62	3.96	2.75	6.92	5.93	4.97	5.96	5.83
	Cash flow	12.03	11.65	11.09	12.34	10.53	14.26	8.67	10.44	13.27	11.92
	Capex	(3.26)	(3.32)	(3.46)	(3.55)	(2.76)	(4.13)	(3.41)	(3.05)	(2.50)	(2.64)
	Free cash flow	8.77	8.33	7.63	8.79	7.77	10.14	5.26	7.39	10.76	9.28
	Book value	35.89	59.14	81.26	78.09	85.19	81.85	88.71	90.11	89.35	88.27
	Shares, m	213	219	258	270	279	289	285	286	290	288
Valuation, ×
Valuation, ×	P/E	30.03	31.56	413.84	48.99	64.89	27.29	29.59	40.61	31.86	25.20
	P/S	2.35	2.73	3.28	3.03	3.10	2.85	2.65	2.99	2.72	1.94
	P/B	3.84	2.55	2.50	2.48	2.10	2.30	1.98	2.25	2.12	1.67
	EV/Sales	3.04	3.10	4.38	4.04	3.99	3.62	3.32	3.68	3.50	2.71
	EV/FCF	20.35	20.53	35.55	29.43	29.55	23.62	41.82	33.68	22.62	22.16
Cash, $m
Cash, $m	Operating cash flow	2,559	2,550	2,865	3,330	2,937	4,126	2,471	2,990	3,844	3,430
	Capex	(693)	(727)	(895)	(957)	(769)	(1,194)	(973)	(874)	(725)	(760)
	Free cash flow	1,866	1,823	1,970	2,373	2,168	2,932	1,498	2,116	3,119	2,670
Balance, $m
Balance, $m	Working capital	1,967	15,291	195	1,009	3,133	2,212	330	2,035	1,512	942
	Total debt	10,550	18,667	18,894	18,081	17,224	17,110	13,886	14,738	17,940	17,621
	Net debt	8,643	4,467	17,641	17,461	14,287	14,706	12,719	13,249	15,639	16,762
	Shareholders’ equity	7,633	12,948	20,994	21,081	23,765	23,677	25,282	25,796	25,890	25,390
Returns, %
Returns, %	ROA	3.75	3.25	0.35	2.05	1.45	3.71	3.16	2.69	3.10	2.98
	ROIC	5.49	5.46	2.44	2.85	1.50	3.67	3.75	3.38	3.61	3.82
	ROE	13.19	10.01	0.94	5.14	3.42	8.44	6.90	5.58	6.60	6.54

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ISRG Intuitive Surgical, Inc.	$151.2B	48.3×	46.4×	+18.54% (above 0%: growing)	+25.54% (above 0%: growing)	+69.33% (above 0%: growing)	67.78%	33.60%	Compare
BDX Becton, Dickinson and Company	$52.8B	57.8×	37.7×	+5.44% (above 0%: growing)	−31.50% (below 0%: shrinking)	−31.57% (below 0%: shrinking)	46.46%	13.31%
MDLN Medline Inc.	$48.1B	—	—	+15.67% (above 0%: growing)	—	+3.42% (above 0%: growing)	28.82%	5.14%	Compare
RMD ResMed Inc.	$34.1B	22.8×	16.6×	+8.58% (above 0%: growing)	+2.32% (above 0%: growing)	−21.31% (below 0%: shrinking)	58.84%	30.66%	Compare
ALC Alcon	$32.1B	50.5×	31.0×	+8.74% (above 0%: growing)	n/m	−0.54% (below 0%: shrinking)	59.33%	0.39%	Compare
WST West Pharmaceutical Services, Inc.	$27.0B	48.7×	37.3×	+13.80% (above 0%: growing)	+19.23% (above 0%: growing)	−20.71% (below 0%: shrinking)	37.74%	20.53%	Compare
SOLV Solventum Corporation	$15.0B	10.4×	39.0×	+2.22% (above 0%: growing)	+1.92% (above 0%: growing)	+144.07% (above 0%: growing)	58.22%	8.19%	Compare
BAX Baxter International Inc.	$13.3B	— (loss-making)	44.7×	+5.34% (above 0%: growing)	+33.33% (above 0%: growing)	+119.48% (above 0%: growing)	34.86%	7.33%	Compare
RGEN Repligen Corporation	$11.7B	234×	112×	+11.93% (above 0%: growing)	−65.38% (below 0%: shrinking)	+27.10% (above 0%: growing)	53.91%	6.85%	Compare
Median of peers	$29.5B	48.5×	39.0×	+10.34%	+10.78%	+15.26%	56.07%	7.76%

All 55 Medical Instruments & Supplies stocks →

Becton, Dickinson and Company (BDX) key facts

Becton, Dickinson and Company (BDX) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, BDX traded at $191.75, a market capitalization of $52.8 billion.
Becton, Dickinson and Company pays an annual dividend of $3.98 per share, a yield of 2.07%, with a payout ratio of 119.7%.
Return on equity was 6.54% and debt-to-equity 0.55.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 1.84 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.